FusionPharm, Inc. (OTC: FSPM), manufacturer of the PharmPod professional cultivation system that’s targeting the vertical farming and cannabis industries, has been rapidly expanding its nationwide presence. For instance, earlier this week, the company announced its first sale to Massachusetts’ legal cannabis market.

On Thursday, the company announced that it would be adding 10,000 additional square feet of manufacturing space to be retrofitted by February 14, 2014. The move is designed to handle both current and future demand for its PharmPod systems.

Read the entire press release discussing the new manufacturing space here:

FusionPharm, Inc. (OTC: FSPM), manufacturer of the PharmPod™ (www.pharmpods.com) professional cultivation system has more than doubled it’s Denver Colorado area manufacturing facility, adding 10,000 additional square feet of manufacturing space.

Management felt that its existing manufacturing space was inadequate to handle current and future order flow effectively.  The new facility is adjacent to the company’s existing facility.

The lease on the new space began on February 1st and retrofit of the space is anticipated to be complete by February 14, 2014.

Additional manufacturing facilities are planned for the east and west coast of the United States in 2014.

About FusionPharm Inc. (FSPM)

FusionPharm, Inc. (FSPM) (www.fusionpharminc.com) was organized to capitalize on opportunities present in the rapidly growing vertical farming and cannabis industries. FusionPharm’s primary focus is the development and deployment of the patent pending PharmPods™ advanced hydroponic commercial cultivation systems. PharmPods are constructed from standard ISO steel shipping containers that are repurposed for use in indoor controlled environment agriculture. Modular, stackable, cost competitive and financeable, PharmPods have become the industry leader for professional, commercial scale indoor plant cultivation

Cautionary Language Concerning Forward-Looking Statements

This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance.  The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved.  Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for FusionPharms products, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in FusionPharms filings with the OTC Markets group. Examples of such forward-looking statements in this release include statements regarding future sales, costs and market acceptance of products as well as regulatory actions at the State or Federal level.  For a more detailed description of the risk factors and uncertainties affecting FusionPharm, Inc. please refer to the Company’s OTC Markets filings, which are available atwww.otcmarkets.com.  FusionPharm, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.